AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03429335 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Teaching session
Description: The cardiology nurse (RN) will have an hour long one-on-one teaching session prior to their pediatric cardiology clinic visit. The RN will go over the youth's cardiac history including the chronic heart disease diagnoses, names and dates of cardiac surgical procedures and cardiac catheterizations, and current cardiac medications and doses. She will also discuss transitioning from pediatric to adult care and healthy lifestyle choices.
Study NCT03429335 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Just TRAC It!
Description: Just TRAC It! (Transitioning Responsibly to Adult Care) is a mobile health intervention that encourages youth to use existing functions on their personal phones to track their health information. The use of Just TRAC It! allows youth to electronically document all medical information that would previously be printed on their MyHealth Passport, but may offer additional functionality in terms of learning to manage their health.
Study NCT03429335 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MyHealth Passport
Description: MyHealth Passport is a customized, wallet-size card that includes the youth's important medical information. The RN will help the youth create a MyHealth Passport online, and print out the card for them.~The same educational intervention will be completed by cardiology nurse using a MyHealth Passport to track their medical information instead of the electronic Just TRAC It!
Study NCT04864756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation based learning
Description: Learning for medical students using simulation based techniques including scenario execution as a complement to conventional teaching methodologies
Study NCT00793988 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vibration-assisted anaesthesia
Description: All anaesthetic injections will consist of xylocaine 1% with 1:100,000 adrenaline and will be administered through a short 30 Gauge needle at a constant slow speed at multiple (6-7) sites along the upper lid by a single oculoplastic consultant.~The vibration device and placebo will be operated by a single oculoplastics fellow. The vibrating device / placebo will be placed on the middle of the forehead 1 cm above the mid-brow point 1 second before the anaesthetic injection is commenced. It will be lifted off the skin every time the injection needle exits the skin and it will be replaced on the same point 1 second before the needle reenters the skin at a new injection site.
Study NCT00793988 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Switched-off vibrating device
Description: The placebo consists of a switched-off vibrating device applied to the test site and a second identical switched-on vibrating device held close (but not touching) the first, which will therefore make the same sound. Care will be taken to ensure that the devices are out of the participants' view. The test and placebo will be randomly assigned to either the first or second eyelid; the right eyelid will be injected first in all patients, as is our routine practice.
Study NCT03443141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: The applied dressing will be embebbed in Vitamin E
Study NCT03443141 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Standard dressing
Description: The applied dressing is a normal one without adding any product to it.
Study NCT00206635 — intervention group
Intervention type: DRUG
Intervention: Interferon beta-1b (Betaseron, BAY86-5046)
Description: Betaseron was not administered as part of this study, only the treatment and disease status was assessed. As part of the MRI analysis Gadolinium was administered in patients who underwent this procedure
Study NCT00681044 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: 16 mcg/kg daily beginning 3 days prior to SCC through day before final SCC
Study NCT00681044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: 70-100 mg/m2/day will be administered intravenously on Days -3 and -2
Study NCT00681044 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Infusion
Description: infusion of previously collected stem cells on Day 0
Study NCT00322777 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spirituality Teaching Program
Description: The Spirituality Teaching Program is a home study program delivered through audio CDs over an 8-week period. The program consists of weekly 90 minute teaching sessions, based on the content of a workshop developed to assist users in developing a more spiritual outlook on life and coping resources. Using didactic comment and storytelling, the following spiritual concepts are addressed in the sessions: self-transcendence, connectedness, forgiveness, self-acceptance, detachment, compassion and gratitude. Each session concludes with a relevant guided visualization practice. In addition, a 15-minute progressive relaxation exercise is included that is to be used on a daily basis. The presented content is nondenominational to ensure compatibility with any beliefs participants may hold.
Study NCT00322777 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Spirituality Teaching Program
Description: The Spirituality Teaching Program is a home study program delivered through audio CDs over an 8-week period. The program consists of weekly 90 minute teaching sessions, based on the content of a workshop developed to assist users in developing a more spiritual outlook on life and coping resources. Using didactic comment and storytelling, the following spiritual concepts are addressed in the sessions: self-transcendence, connectedness, forgiveness, self-acceptance, detachment, compassion and gratitude. Each session concludes with a relevant guided visualization practice. In addition, a 15-minute progressive relaxation exercise is included that is to be used on a daily basis. The presented content is nondenominational to ensure compatibility with any beliefs participants may hold.
Study NCT01419002 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: neoadjuvant RTx
Description: Neoadjuvant radiotherapy with external intensity modulated beam radiation followed by duodenopancreatectomy and adjuvant chemotherapy according to German S3 guidelines.
Study NCT01419002 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgery and adjuvant chemotherapy according to German S3-guidelines
Study NCT03217747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV
Study NCT03217747 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ivuxolimab
Description: Given IV
Study NCT03217747 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT03217747 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Utomilumab
Description: Given IV
Study NCT03524846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ascorbic Acid 300 MG
Description: Ascorbic acid 300 mg was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
Study NCT03524846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ascorbic Acid 600 MG
Description: Ascorbic acid 600 mg was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
Study NCT03524846 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
Study NCT04604600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amyloid PET
Description: Dynamic PET acquisition for 70 minutes will be acquired after injection of 10±5 mCi 11C-PiB.
Study NCT01176201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV337 suspension
Description: 400 mg experimental
Study NCT01176201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SLV337 capsule
Description: 5 x 200 mg immediate release capsule
Study NCT02909530 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-FNB with EZ Shot 2 19G first
Description: Both needles (EZ Shot 3Plus 19G and EZ Shot 2 19G) will be used for endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) in each patient following a predetermined random order which needle is used to pass through the tumor first.
Study NCT02879474 — intervention group
Intervention type: BEHAVIORAL
Intervention: Melanoma scale questionnair
Study NCT01013454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline free base patch
Description: varenicline transdermal delivery system (6.0 mg payload \[drug amount loaded in each patch\]) will be applied to the upper back over a single 24 hour period
Study NCT02713282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 3 month formulation (PP3M)
Description: Participants will receive intramuscular injection of Paliperidone Palmitate 3-Month Formulation (PP3M) on Day 1 at a starting dose of 175 milligram equivalent (mg eq) up to 525 mg eq based on last Paliperidone Palmitate 1-Month Formulation (PP1M) dose (at a dose of 3.5-fold multiple of the participant's last PP1M dose). Subsequent PP3M injections will be given at Month 3, Month 6, and Month 9 and dose can be adjusted flexibly in increments within the range of 175 to 525 mg eq.
Study NCT03701529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: 1.5-2.5 vol % sevoflurane is used for maintenance of anesthesia.
Study NCT03284710 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ALVAC-HIV (vCP2438)
Description: Expresses the gene products ZM96 gp120 (clade C strain) linked to the sequences encoding the HIV-1 transmembrane (TM) anchor sequence of gp41 (28 amino acids clade B LAI strain) and gag and pro (clade B LAI strain); formulated as a lyophilized vaccine for injection at a viral titer ≥ 1 × 10\^6 cell culture infectious dose (CCID)50 and \< 1 × 10\^8 CCID50 (nominal dose of 10\^7 CCID50) and reconstituted with 1mL of sterile sodium chloride solution (NaCl 0.4%) for intramuscular (IM) injection as a single dose
Study NCT03701529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 2-5 mcg/ml of propofol is used for maintenance of anesthesia.
Study NCT00414037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Study NCT03284710 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent Subtype C gp120/MF59
Description: Consists of 2 subtype C recombinant monomeric proteins, TV1.C gp120 Env and 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant (an oil-in-water emulsion); delivered as a 0.5 mL IM injection
Study NCT03284710 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent Subtype C gp120 admixed with Al(OH)3 Suspension
Description: Consists of 2 subtype C recombinant monomeric proteins, TV1.C gp120 Env and 1086.C gp120 Env, each at a dose of 100 mcg, admixed with Aluminum Hydroxide Suspension (\~625 mcg aluminum content); delivered as a 0.5 mL IM injection
Study NCT03284710 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent Subtype C gp120
Description: Consists of 2 subtype C recombinant monomeric proteins, TV1.C gp120 Env and 1086.C gp120 Env, each at a dose of 100 mcg, mixed with sodium chloride for injection, 0.9%; delivered as a 0.5 mL IM injection
Study NCT00414037 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-treatment
Study NCT03040999 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
Study NCT03040999 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline or dextrose solution administered as an IV infusion Q3W
Study NCT03040999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 100 mg/m\^2 administered as an IV infusion Q3W
Study NCT03040999 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: 100 mg/m\^2 administered as an IV infusion Q3W
Study NCT03040999 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated Fractionation (AFX) Radiotherapy
Description: 70 Gray (Gy) given in 35 fractions over 6 weeks
Study NCT03040999 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Accelerated Fractionation (AFX) Radiotherapy
Description: 70 Gray (Gy) given in 35 fractions over 6 weeks
Study NCT03040999 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard Fractionation (SFX) Radiotherapy
Description: 70 Gy given in 35 fractions over 7 weeks
Study NCT03040999 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Standard Fractionation (SFX) Radiotherapy
Description: 70 Gy given in 35 fractions over 7 weeks
Study NCT03519074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-1 combined with cisplatin
Description: Cisplatin 60mg/m2, day 1, every 21 days Oral TS-1 30mg/m2 bd, days 1-14, every 21 days (absolute dose of oral TS-1 will be 40-60mg bd days 1-14, every 21 days, depending on body surface area)
Study NCT03753334 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MAG-EPA
Description: 5g/day of omega-3-rich fish oil including 4g of purified monoglycerides EPA, capsules, taken once daily, for 12 months
Study NCT03753334 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: 5g/day of placebo (high oleic sunflower oil), capsules, taken once daily, for 12 months
Study NCT03316196 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COGENT COGNITIVE TRAINING
Description: Computer-administered cognitive training program. COGENT is a modified working memory capacity task designed to train cognitive functioning. COGENT was designed to contain high interference across trials. By requiring repeated practice with utilization of interference control across trials, COGENT is thought to enhance plasticity of cognitive systems and improve performance. That is, training is based on the premise that learning-based neural changes will occur via repeated exposure to a task demanding cognitive control resources
Study NCT03316196 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Non training computer condition
Description: The non-training condition requires participants to complete a similar computer task for the same length of time. The non-training is a modified working memory capacity task designed to be inert. The non-training condition was designed to contain relatively less interference demands across trials. Participants are required to remember the same total number of items as in COGENT (i.e., storage requirements were equivalent), but the task contains relatively less interference inherent in the task.
Study NCT05070936 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: vestibular rehabilitation
Description: Vestibular rehabilitation consisted of a total of 4 sessions, rearranged every 15 days. These exercises were prepared gradually to increase the vestibulo-ocular reflex and vestibulospinal reflex. The following exercises were done with the patients: both sitting and standing gaze stabilization exercises, neck joint range of motion exercises, 20 minutes walks outside, walking backward both open-and-closed eyes, and walking in tandem with both open-and-closed eyes. The therapist gave the patients a home exercise program. It was emphasized that the exercises should be applied as 10 repetitions. After the session, the exercises shown to the patients were explained in written form and given as home exercises. They were also asked to do home exercises 3 times a day, 10 repetitions, for 15 days. Evaluation of the patients was done at the beginning of the first session and the 4th session. Thus, 3 separate exercise sessions and a home exercise program were applied to the patients.
Study NCT03661723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a drug (an antibody) that may treat cancer by working with the immune system
Study NCT03661723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (also known as Avastin) is designed to prevent or slow down the growth of cancer cells by blocking the growth of blood vessels.
Study NCT03661723 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Re-irradiation
Description: Radiotherapy destroys cancer cells using radiation aimed at a cancer from a machine
Study NCT04237467 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There was no intervention.
Study NCT01181388 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: administration of tirofiban by thrombus aspiration catheter in infarct-related artery
Description: a bolus of 10ug/kg tirofiban administration via thrombus aspiration catheter followed by 0.1ug/kg/min for 12 hours after PCI
Study NCT01181388 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: administration of tirofiban by guide catheter
Description: a bolus of 10ug/kg tirofiban administration via guide catheter followed by 0.1ug/kg/min for 12 hours after PCI
Study NCT04108364 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voice adaptive training for aphasia
Description: Training with the VoiceAdapt tablet-based therapy app 25 hours (1 hr/day x 5 days/week x 5 weeks)
Study NCT03985761 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Telerehabilitation using HoVRS
Description: The Home Virtual Rehabilitation System (HoVRS) integrates a Leap Motion controller, a passive arm support and a suite of custom designed hand rehabilitation simulations. The Leap Motion provides camera based measurement of finger joint positions, allowing for integrated virtual arm and finger training. If the patient's arm is severely impaired, a forearm orthosis that counter-balances gravity to provide graded support to the arm during activity is issued to the subject. In this study, we utilize 3 task-based simulations that train hand manipulation and arm transport. One simulation trains hand opening integrated with pronation and supination, a second trains wrist movement, by presenting targets that subjects navigate a plane over and around buildings to collect, a third simulation, trains shoulder and elbow disassociation in a horizontal plane integrated with hand opening.
Study NCT03985761 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home Telerehabilitation using HoVRS
Description: The Home Virtual Rehabilitation System (HoVRS) integrates a Leap Motion controller, a passive arm support and a suite of custom designed hand rehabilitation simulations. The Leap Motion provides camera based measurement of finger joint positions, allowing for integrated virtual arm and finger training. If the patient's arm is severely impaired, a forearm orthosis that counter-balances gravity to provide graded support to the arm during activity is issued to the subject. In this study, we utilize 3 task-based simulations that train hand manipulation and arm transport. One simulation trains hand opening integrated with pronation and supination, a second trains wrist movement, by presenting targets that subjects navigate a plane over and around buildings to collect, a third simulation, trains shoulder and elbow disassociation in a horizontal plane integrated with hand opening.
Study NCT02945579 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT
Study NCT02945579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02945579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02945579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02860494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months. Dose regimens will be identical, regardless of the dose-strength of the topical formulation. The topical formulation will be applied onto areas of the face affected by FA by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
Study NCT02945579 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole Breast Irradiation
Description: Undergo whole breast irradiation
Study NCT04204447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hepatitis C Educational Brochure
Description: Subjects will receive information about Hepatitis C through a brochure
Study NCT04204447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hepatitis C Educational Video
Description: Subjects will receive information about Hepatitis C through a video
Study NCT04024865 — intervention group
Intervention type: DRUG
Intervention: Domperidone
Description: Women who received a prescription for domperidone (ATC A03FA03) during the six months following delivery.
Study NCT04024865 — intervention group
Intervention type: DRUG
Intervention: No domperidone
Description: Women with no prescription for domperidone during the six months following delivery.
Study NCT01320189 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Differences in protein content of meals
Description: Differences in protein content (energy percent) of meals
Study NCT04645368 — intervention group
Intervention type: DRUG
Intervention: bovhyaluronidase azoxymer
Description: 3000 IU intramuscularly once every 5 days with a course of 15 injections